|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
In the context of COVID-19 pandemic, a report on ivermectin suppression of SARS-CoV-2 viral replication in cell cultures has been published, and the use of this medication seems to be potentially useful for the therapy. IVM safety profile and IVM wide spectrum enables to move forward with the investigation in patients infected by SARS-CoV-2 as a proof-of-concept of its possible use in the management of patients with COVID-19, given the current pandemic situation.
Description: Number of patients in whom the SARS-CoV-2 viral load decreases after Ivermectin treatmentMeasure: Reduction in SARS-CoV-2 viral load Time: 1 - 5 days
Description: Clinical symptoms will be assessed after the treatment with the study drugMeasure: Number of patients with partial or complete response in COVID-19 clinical symptoms Time: 1 - 7 days
Description: Effect of Ivermectin therapy on severity indicators such as need of intensive care unit and assisted ventilation, or mortalityMeasure: Number of patients with worsening in the clinical condition Time: 1 - 7 days
Description: Ivermectin safety profile will be evaluated according to Common Terminology Criteria for Adverse Events (CTCAE version 4.0)Measure: Number of patients with adverse events as a measure of safety and tolerability Time: 1 month
Description: Effect of Ivermectin therapy on the onset of SARS-CoV-2 antibodies through the determination of serological changesMeasure: Evaluation of reactivity of the antibodies against SARS-CoV-2 Time: 1 month
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports